← REGENERON PHARMACEUTICALS, INC.
| Annual Trend | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||||
| Current assets: | |||||||||||
| Cash and Cash Equivalents, at Carrying Value | $535.2m | $812.7m | $1.5b | $1.6b | $2.2b | $2.9b | $3.1b | $2.7b | $2.5b | $3.1b | |
| Prepaid Expense and Other Assets, Current | $130.5m | $225.0m | $243.3m | $387.1m | $160.8m | $332.4m | $411.2m | $386.6m | $349.2m | $474.8m | |
| Inventory, Net | $399.4m | $726.1m | $1.2b | $1.4b | $1.9b | $2.0b | $2.4b | $2.6b | $3.1b | $3.2b | |
| Assets, Current | $3.2b | $4.3b | $6.4b | $7.7b | $9.8b | $14.0b | $15.9b | $19.5b | $18.7b | $18.0b | |
| Property, Plant and Equipment, Net | $2.1b | $2.4b | $2.6b | $2.9b | $3.2b | $3.5b | $3.8b | $4.1b | $4.6b | $5.1b | |
| Intangible Assets, Net (Excluding Goodwill) | — | — | — | — | — | — | $915.5m | $1.0b | $1.1b | $1.3b | |
| Operating Lease, Right-of-Use Asset | — | — | — | — | — | — | — | $78.0m | $217.4m | $245.8m | |
| Other Assets, Noncurrent | $20.3m | $77.9m | $127.4m | $144.7m | $168.1m | $222.8m | $336.4m | $444.1m | $1.1b | $1.8b | |
| Additional Financial Items | |||||||||||
| Accounts Receivable, after Allowance for Credit Loss, Current | $1.3b | $1.5b | $1.7b | $2.1b | $3.1b | $6.0b | $5.3b | $5.7b | $6.2b | $5.7b | |
| Assets | $7.0b | $8.8b | $11.7b | $14.8b | $17.2b | $25.4b | $29.2b | $33.1b | $37.8b | $40.6b | |
| LIABILITIES AND EQUITY | |||||||||||
| Current liabilities: | |||||||||||
| Operating Lease, Liability, Current | — | — | — | — | — | — | — | $19.0m | $30.3m | $37.8m | |
| Accounts Payable, Current | — | $178.2m | $218.2m | $418.1m | $475.5m | $564.0m | $589.2m | $606.6m | $789.5m | $939.0m | |
| Operating Lease, Liability, Noncurrent | — | — | — | — | — | — | — | $68.7m | $204.1m | $229.0m | |
| Deferred Revenue, Current | $231.7m | $320.1m | $452.5m | $591.7m | $577.7m | $73.3m | $69.8m | $126.7m | $185.7m | $208.7m | |
| Deferred Revenue, Noncurrent | $830.8m | $629.2m | $452.5m | $591.7m | $577.7m | $73.3m | $69.8m | $126.7m | $185.7m | $208.7m | |
| Long-term Debt, Excluding Current Maturities | — | — | — | $0 | $2.0b | $2.0b | $2.0b | $2.0b | $2.0b | $2.0b | |
| Liabilities, Current | $1.2b | $1.1b | $1.4b | $2.1b | $2.7b | $3.9b | $3.1b | $3.4b | $3.9b | $4.4b | |
| Other Liabilities, Noncurrent | $100.4m | $152.1m | $361.7m | $286.0m | — | $680.2m | $638.0m | $854.1m | $1.6b | $2.0b | |
| Liabilities | $2.5b | $2.6b | $3.0b | $3.7b | $6.1b | $6.7b | $6.6b | $7.1b | $8.4b | $9.3b | |
| Stockholders’ equity: | |||||||||||
| Preferred Stock, Value, Issued | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | |
| Additional Paid in Capital | $3.0b | $3.5b | $3.9b | $4.4b | $6.7b | $8.1b | $9.9b | $11.4b | $12.9b | $14.0b | |
| Retained Earnings (Accumulated Deficit) | $1.7b | $2.9b | $5.3b | $7.4b | $10.9b | $19.0b | $23.3b | $27.3b | $31.7b | $35.8b | |
| Accumulated Other Comprehensive Income (Loss), Net of Tax | ($12.8m) | $640k | ($12.3m) | $21.1m | $29.3m | ($26.2m) | ($238.8m) | ($80.9m) | ($7.9m) | $77.5m | |
| Stockholders' Equity Attributable to Parent | $4.4b | $6.1b | $8.8b | $11.1b | $11.0b | $18.8b | $22.7b | $26.0b | $29.4b | $31.3b | |
| Liabilities and Equity | $7.0b | $8.8b | $11.7b | $14.8b | $17.2b | $25.4b | $29.2b | $33.1b | $37.8b | $40.6b |
Values abbreviated: b = billions, m = millions, k = thousands. Per share data in USD.